Incannex Healthcare authorised a share repurchase programme of up to US$20 million, saying the initiative reflects management’s view that the company’s market valuation fails to capture progress in its late-stage clinical pipeline. The Melbourne- and New York-listed biopharmaceutical firm said buybacks may be conducted through open-market purchases, privately negotiated deals or other methods permitted under Rule 10b5-1 and Rule 10b-18. The stock jumped roughly 35–40 per cent in pre-market US trading on Friday. Separately, networking-equipment maker Ubiquiti Inc. unveiled a US$500 million stock-buyback authorisation and reported stronger-than-expected fiscal fourth-quarter results. Adjusted earnings rose to US$3.54 a share, beating the lone analyst estimate of US$2.23, while revenue climbed 49.6 per cent from a year earlier. The company also lifted its quarterly dividend, contributing to a pre-market gain of about 12 per cent. The fresh buyback authorisations add to a flurry of corporate repurchases announced this month, underscoring companies’ willingness to return cash to shareholders even as capital-market conditions remain volatile.